Table 2.

BMD changes at L2–4 in the five studies of calcitriol monotherapy

Study	Patients (n)	Pretreatment (g/cm2)	12 or 24 months (g/cm2)	Percentage change	Absolute change
Xia et al26
Caltrate D	72	0.930±0.126	0.935±0.137b	0.83±3.88	0.008±0.036
Calcitriol + Caltrate D	70	0.916±0.132	0.945±0.130c,f	2.84±4.04	0.025±0.034
He et al36
Caltrate D	150	0.928±0.106	0.933±0.121
Calcitriol + Caltrate D	150	0.970±0.184	0.968±0.186
Xie et al27
Control	51	0.902±0.155	0.902±0.154	0.19±4.05
Calcitriol + Caltrate D	47	0.907±0.130	0.959±0.131c,f	5.94±4.62
He et al28
Caltrate D	58	0.76±0.12	0.71±0.13
Calcitriol + Caltrate D	57	0.75±0.14	0.82±0.18b,f
Zhu et al29
Caltrate D	49	0.75±0.02	0.74±0.02		−0.01±0.09
Calcitriol + Caltrate D	52	0.76±0.03	0.79±0.04b,f		0.03±0.06
Yang et al30
Caltrate D	63	0.74±0.03	0.75±0.04		0.01±0.05
Calcitriol + Caltrate D	63	0.73±0.04	0.84±0.05c,f		0.11±0.17

Notes: 12 or 24 months denotes 12²⁶–³⁰ or 24³⁶ months after treatment. Values are expressed as the mean ± standard deviation.

^bP<0.05.

^cP<0.01 versus baseline by paired t-test.

^fP<0.01 compared between two groups by analysis of covariance adjusted for baseline BMD.

Abbreviation: BMD, bone mineral density.